Morgan Stanley Issues Positive Forecast for Cooper Companies (NASDAQ:COO) Stock Price

by · The Markets Daily

Cooper Companies (NASDAQ:COO – Get Free Report) had its price target increased by equities researchers at Morgan Stanley from $76.00 to $83.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical device company’s stock. Morgan Stanley’s price target points to a potential upside of 4.70% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Mizuho set a $100.00 price objective on shares of Cooper Companies and gave the company an “outperform” rating in a research report on Friday. Weiss Ratings reissued a “hold (c-)” rating on shares of Cooper Companies in a research note on Monday, December 1st. Barclays reaffirmed an “overweight” rating and set a $91.00 price objective on shares of Cooper Companies in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $100.00 target price (up previously from $94.00) on shares of Cooper Companies in a research report on Friday. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $71.00 price target (up from $64.00) on shares of Cooper Companies in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average price target of $91.85.

View Our Latest Stock Analysis on Cooper Companies

Cooper Companies Stock Performance

COO traded down $2.12 during trading on Monday, hitting $79.28. The company’s stock had a trading volume of 1,093,597 shares, compared to its average volume of 2,439,468. Cooper Companies has a one year low of $61.78 and a one year high of $100.47. The business’s 50 day simple moving average is $72.29 and its 200-day simple moving average is $71.61. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. The firm has a market cap of $15.76 billion, a PE ratio of 42.21, a P/E/G ratio of 1.94 and a beta of 1.05.

Cooper Companies (NASDAQ:COO – Get Free Report) last released its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the business earned $1.04 earnings per share. Cooper Companies’s quarterly revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its board has authorized a share repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were bought at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the acquisition, the director owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. This represents a 52.95% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.98% of the stock is owned by insiders.

Institutional Trading of Cooper Companies

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bell Investment Advisors Inc boosted its position in Cooper Companies by 106.3% during the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 219 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in Cooper Companies during the 1st quarter valued at about $33,000. J.Safra Asset Management Corp boosted its holdings in Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after acquiring an additional 340 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in shares of Cooper Companies during the second quarter worth about $36,000. Finally, GKV Capital Management Co. Inc. acquired a new position in shares of Cooper Companies during the first quarter valued at about $40,000. 24.39% of the stock is currently owned by institutional investors.

About Cooper Companies

(Get Free Report)

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

Further Reading